Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Characterization of Bleeding in Hemophilia Carriers and Comparison to Women with Type 1 Von Willebrand Disease, Type 3 Von Willebrand Disease Obligate Carriers and Controls

Natasha Amrita Satkunam, MBBS, MSc, Johnny Mahlangu, MD, Christoph Bidlingmaier, MD PD, Dr. MD, Maria Eva Mingot-Castellano, PhD, Meera B. Chitlur, MD, Patrick F. Fogarty, MD, Adam Cuker, MD MS, Maria Elisa Mancuso, MD PhD, Pal André Holme, PhD MD, Julie Grabell, BA, CCRP, Wilma Hopman, MA, Prasad Mathew, MD, Paula D. James, MD

Blood (2016) 128 (22): 875.

https://doi.org/10.1182/blood.V128.22.875.875

Published: 2016

Journal Articles

Prospective Data Collection on Patients with Fibrinogen and Factor XIII Deficiencies: Prelimary Results of the PRO-RBDD Project

Blood (2014) 124 (21): 2838.

https://doi.org/10.1182/blood.V124.21.2838.2838

Published: 2014

Journal Articles

Influence of Factor V G1691A or Prothrombin G20210A Mutation On Inhibitor Development in Patients with Severe Hemophilia A - an Israeli-German Database Study.

Gili Kenet, MD, Christoph Bidlingmaier, Carmen Escuriola Ettingshausen, MD, Sven Gutsche, MD, Susan Halimeh, MD, Verena Janssen, MD, Karin Kurnik, MD, Ulrike Nowak-Gottl, MD

Blood (2012) 120 (21): 2234.

https://doi.org/10.1182/blood.V120.21.2234.2234

Published: 2012

Journal Articles

Patients with Hermansky-Pudlak Syndrome Show Various Phenotypes Caused by Novel Mutations,

Kirstin Sandrock, PhD, Karin Kurnik, MD, Stephan Ehl, MD, Christoph Bidlingmaier, Lea Nakamura, Nina Rombach, MD, Sophie Schäfer, MD, Barbara Zieger, MD

Blood (2011) 118 (21): 3286.

https://doi.org/10.1182/blood.V118.21.3286.3286

Published: 2011

Journal Articles

A Genome Wide Association Study Identifies Novel Susceptibility Genes for Pediatric Venous Thrombosis,

Astrid Arning, PhD, Milan Hiersche, Christoph Bidlingmaier, Monika Stoll, PhD, Ulrike Nowak-Gottl, MD

Blood (2011) 118 (21): 3336.

https://doi.org/10.1182/blood.V118.21.3336.3336

Published: 2011

Journal Articles

Coagulation Factor Activity Level and Clinical Bleeding Severity in Rare Bleeding Disorders: Results From the European Network of Rare Bleeding Disorders (EN-RBD),

Blood (2011) 118 (21): 3312.

https://doi.org/10.1182/blood.V118.21.3312.3312

Published: 2011

Journal Articles

A Predictive Model for the Development of High-Responding Inhibitor In Children with Severe and Moderate Hemophilia A- Results of a Multicenter Cohort Study

Susanne Holzhauer, MD, Christoph Bidlingmaier, MD, Carmen Escuriola Ettingshausen, MD, Susan Halimeh, MD, Alfonso Iorio, MD, Gili Kenet, MD, Brigitte Pautard, MD, Ulrike Nowak-Gottl, MD

Blood (2010) 116 (21): 710.

https://doi.org/10.1182/blood.V116.21.710.710

Published: 2010

Journal Articles

Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study

Lesley Mitchell, Moritz Lambers, Silke Flege, Gili Kenet, Valerie Li-Thiao-Te, Susanne Holzhauer, Christoph Bidlingmaier, Michael C. Frühwald, Christine Heller, Wolfgang Schmidt, Brigitte Pautard, Ulrike Nowak-Göttl

Blood (2010) 115 (24): 4999–5004.

https://doi.org/10.1182/blood-2010-01-263012

Published: 2010

Journal Articles

Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature.

Alfonso Iorio, MD, Susan Halimeh, MD, Christoph Bidlingmaier, MD, Leonardo R. Brandao, MD, Carmen Escuriola-Ettingshausen, MD, Neil A Goldenberg, MD, PhD, Alessandro Gringeri, MD, MSc, Susanne Holzhauer, MD, Gili Kenet, MD, PhD, Ralf Knoefler, MD, Wolfhart Kreuz, MD, Karin Kurnik, MD, Daniela Manner, MD, Emanuela Marchesini, MD, Maura Marcucci, MD, Elena Santagostino, MD, PhD, Guy Young, MD, Pier Mannuccio Mannucci, MD, Ulrike Nowak-Gottl, MD

Blood (2009) 114 (22): 3154.

https://doi.org/10.1182/blood.V114.22.3154.3154

Published: 2009

Journal Articles

New Early Prophylaxis Regimen That Avoids Immunological Danger Signals Can Reduce Factor Eight (FVIII) Inhibitor Development Independent From Product Type Used.

Guenter K.H. Auerswald, MD, Christoph Bidlingmaier, Werner Engl, Heidi Chehadeh, Birgit M Reipert, PhD, Karin Kurnik, MD

Blood (2009) 114 (22): 221.

https://doi.org/10.1182/blood.V114.22.221.221

Published: 2009

Journal Articles

Case Report on a Female Patient with Congenital Haemophilia a and An Acquired Type-2 Inhibitor to FVIII

Karin Kurnik, Christoph Bidlingmaier

Blood (2008) 112 (11): 4525.

https://doi.org/10.1182/blood.V112.11.4525.4525

Published: 2008

Journal Articles

Presence of Factor V Leiden or Prothrombin Mutation Influence Inhibitor Development in Children with Severe Hemophilia A: Data of a Multicenter Cohort Study

Karin Kurnik, Christoph Bidlingmaier, Christine During, Susan Halimeh, Rosemarie Schobess, Ulrike Nowak-Gottl, MD

Blood (2008) 112 (11): 242.

https://doi.org/10.1182/blood.V112.11.242.242

Published: 2008

Journal Articles

Effects of “Primary Prophylaxis” and “On-Demand” Therapy on the Clinical Expression of Severe Hemophilia A in Children - Results of a Multicenter Study.

Rosemarie Schobess, Karin Kurnik, Wolfhart Kreuz, Frauke Friedrichs, Anne Krumpel, Christoph Bidlingmaier, Carmen Escuriola Ettingshausen, Ulrike Nowak-Gottl

Blood (2007) 110 (11): 3146.

https://doi.org/10.1182/blood.V110.11.3146.3146

Published: 2007

Journal Articles

Long-Term Safety and Efficacy Data on Childhood Venous Thrombosis Treated with Enoxaparin: An Open Label Survey of Once-Daily Versus Twice-Daily Administration.

Ulrike Nowak-Gottl, MD, Christine During, MD, Christoph Bidlingmaier, MD, Nick Merkel, MD, Rosemarie Schobess, MD

Blood (2005) 106 (11): 549.

https://doi.org/10.1182/blood.V106.11.549.549

Published: 2005

Journal Articles

Factor V G1691A and Factor II G20210A Mutations and Clinical Expression of Severe Hemophilia A (< 2%) in Children: Impact on Bleeding Episodes and Joint Damage.

Ulrike Nowak-Gottl, MD, Carmen Escuriola, MD, Rosemarie Schobess, MD, Christine Duering, MD, Christoph Bidlingmaier, MD, Hartmut Pollmann, MD, Sylvia Horneff, MD, Karin Kurnik, MD

Blood (2004) 104 (11): 3095.

https://doi.org/10.1182/blood.V104.11.3095.3095

Published: 2004

NARROW

Characterization of Bleeding in Hemophilia Carriers and Comparison to Women with Type 1 Von Willebrand Disease, Type 3 Von Willebrand Disease Obligate Carriers and Controls

Prospective Data Collection on Patients with Fibrinogen and Factor XIII Deficiencies: Prelimary Results of the PRO-RBDD Project

Influence of Factor V G1691A or Prothrombin G20210A Mutation On Inhibitor Development in Patients with Severe Hemophilia A - an Israeli-German Database Study.

Patients with Hermansky-Pudlak Syndrome Show Various Phenotypes Caused by Novel Mutations,

A Genome Wide Association Study Identifies Novel Susceptibility Genes for Pediatric Venous Thrombosis,

Coagulation Factor Activity Level and Clinical Bleeding Severity in Rare Bleeding Disorders: Results From the European Network of Rare Bleeding Disorders (EN-RBD),

A Predictive Model for the Development of High-Responding Inhibitor In Children with Severe and Moderate Hemophilia A- Results of a Multicenter Cohort Study

Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study

Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature.

New Early Prophylaxis Regimen That Avoids Immunological Danger Signals Can Reduce Factor Eight (FVIII) Inhibitor Development Independent From Product Type Used.

Case Report on a Female Patient with Congenital Haemophilia a and An Acquired Type-2 Inhibitor to FVIII

Presence of Factor V Leiden or Prothrombin Mutation Influence Inhibitor Development in Children with Severe Hemophilia A: Data of a Multicenter Cohort Study

Effects of “Primary Prophylaxis” and “On-Demand” Therapy on the Clinical Expression of Severe Hemophilia A in Children - Results of a Multicenter Study.

Long-Term Safety and Efficacy Data on Childhood Venous Thrombosis Treated with Enoxaparin: An Open Label Survey of Once-Daily Versus Twice-Daily Administration.

Factor V G1691A and Factor II G20210A Mutations and Clinical Expression of Severe Hemophilia A (< 2%) in Children: Impact on Bleeding Episodes and Joint Damage.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only